Antimicrobial treatment for 7 versus 14 days in patients with bacteremia: a meta-analysis of randomized controlled trials.|https://dx.doi.org/10.1007/s15010-025-02562-4
Clostridioides difficile evolution in a tertiary German hospital through a retrospective genomic characterization.|https://dx.doi.org/10.1007/s15010-025-02576-y
Fidaxomicin Treatment of Clostridioides difficile Infections and Recurrences in Children and Adolescents: A Retrospective Multicenter Study.|https://dx.doi.org/10.1016/j.jpeds.2025.114681
Caffeic acid phenethyl ester protects Clostridioides difficile infection by toxin inhibition and microbiota modulation.|https://dx.doi.org/10.7554/eLife.101757
Evaluating Disparities in Recurrent Clostridioides difficile Infection (CDI) and Fecal Microbiota Transplant (FMT) Treatment using Geospatial and Social Vulnerability Analytic Tools.|https://dx.doi.org/10.1053/j.gastro.2025.05.028
The ladder of regulatory stringency and balance: an application to the US FDA's regulation of bacterial live therapeutics.|https://dx.doi.org/10.1080/19490976.2025.2517377
Extracellular DNA filaments associated with surface polysaccharide II give Clostridioides difficile biofilm matrix a network-like structure.|https://dx.doi.org/10.1038/s41522-025-00751-5
Receptor-targeted Lactococcus lactis mitigate Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.micres.2025.128221
Efficacy, safety, pharmacokinetics, and associated microbiome changes of ibezapolstat compared with vancomycin in adults with Clostridioides difficile infection: a phase 2b, randomised, double-blind, active-controlled, multicentre study.|https://dx.doi.org/10.1016/j.lanmic.2025.101126
Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.|https://dx.doi.org/10.7326/ANNALS-24-03285
Probiotics Ameliorate Histological Alterations and Prevent Increases in Cytokine and Toxin Levels in Mice Infected with Various Clostridioides difficile Strains.|https://dx.doi.org/10.1007/s12602-025-10586-3
Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.|https://dx.doi.org/10.1128/aac.00515-25
Engrafting gut bacteriophages have potential to modulate microbial metabolism in fecal microbiota transplantation.|https://dx.doi.org/10.1186/s40168-025-02046-5
Efficacy of three chemical disinfectants and steam against Clostridioides difficile endospores on nylon carpet with two different backing systems.|https://dx.doi.org/10.1128/aem.00861-25
Phenotypic analysis of various Clostridioides difficile ribotypes reveals consistency among core processes.|https://dx.doi.org/10.1128/aem.00964-25
Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1080/19490976.2025.2520412
Real-world use of bezlotoxumab to prevent recurrent Clostridioides difficile infections: a single-center experience and meta-analysis.|https://dx.doi.org/10.1177/17562848251346593
Faecal Microbiota Transplantation as an Adjuvant Treatment for Extraintestinal Disorders: Translating Insights from Human Medicine to Veterinary Practice.|https://dx.doi.org/10.3390/vetsci12060541
Possible Applications of Fecal Microbiota Transplantation in the Pediatric Population: A Systematic Review.|https://dx.doi.org/10.3390/biomedicines13061393
Phenotypic and genomic characterization of Clostridioides difficile strains involved in multiple recurrences.|https://dx.doi.org/10.1016/j.anaerobe.2025.102980
Healthcare-Associated Clostridioides difficile Infection: A Hospital-Based Retrospective Study in North Eastern Romania.|https://dx.doi.org/10.3390/microorganisms13061377
Leveraging diverse cell death patterns in osteosarcoma patients and identification of the function of FADS2 in osteosarcoma cells.|https://dx.doi.org/10.1038/s41598-025-05480-5
Fecal microbiota transplantation: Current evidence and future directions.|https://dx.doi.org/10.3949/ccjm.92a.24107
The interplay between host immunity and Clostridioides difficile infection.|https://dx.doi.org/10.1128/mbio.03562-24
Fecal Microbiota Transplantation (FMT) in Clostridium difficile Infection: A Paradigm Shift in Gastrointestinal Microbiome Modulation.|https://dx.doi.org/10.7759/cureus.85054
Fecal Microbiome Transplantation for Recurrent CDI: Treatment Efficacy and Safety with Oral Capsules.|https://dx.doi.org/10.15403/jgld-5990
Uncertain Benefits of Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.1001/jamanetworkopen.2025.21084
Oral Vancomycin for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.|https://dx.doi.org/10.1001/jamanetworkopen.2025.17834
Recurrent Clostridioides difficile Infection (CDI) in Patients Treated With Vancomycin at Johns Hopkins Aramco Healthcare (JHAH), Dhahran, Saudi Arabia.|https://dx.doi.org/10.7759/cureus.85116
Clinician Management Preferences for Clostridioides difficile Infection in Adults: A 2024 Emerging Infections Network Survey.|https://dx.doi.org/10.1093/ofid/ofaf335
Fecal microbiota transplantation for prevention of recurrent acute cholangitis. Review of four published cases.|https://dx.doi.org/10.17235/reed.2025.11404/2025
Turkish Version of the Cardiac Distress Inventory and Cardiac Distress Inventory Short Form: A Validity and Reliability Study.|https://dx.doi.org/10.5543/tkda.2025.94460
Lyophilised fecal microbiota transfer in capsules for recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.ijantimicag.2025.107561
A review of engraftment assessments following fecal microbiota transplant.|https://dx.doi.org/10.1080/19490976.2025.2525478
The role of fecal microbiota transplantation in selected neurodegenerative diseases and neurodevelopmental disorders.|https://dx.doi.org/10.5114/pg.2024.146118
